Trevi Therapeutics (TRVI) Operating Expenses (2018 - 2025)

Trevi Therapeutics' Operating Expenses history runs 8 years deep, the most recent figure standing at $10.2 million for Q4 2025.

• On a quarterly basis, Operating Expenses fell 16.52% year-over-year to $10.2 million in Q4 2025; TTM through Mar 2026 was $37.9 million, a 4.44% decrease from a year earlier, with the FY2025 full-year figure at $49.3 million, down 4.26% from the prior year.
• Operating Expenses retreated to $10.2 million in Q4 2025 per TRVI's latest filing, from $13.9 million in the prior quarter.
• Across five years, Operating Expenses topped out at $14.1 million in Q3 2024 and bottomed at $6.7 million in Q4 2022.
• The 5-year median for Operating Expenses is $8.9 million (2023), against an average of $9.8 million.
• Across the five-year window, Operating Expenses dropped 19.53% in 2022 and soared 58.54% in 2024, its largest moves.
• Year by year, Operating Expenses stood at $8.3 million in 2021, then slipped by 19.53% to $6.7 million in 2022, then soared by 34.19% to $8.9 million in 2023, then soared by 37.05% to $12.2 million in 2024, then slipped by 16.52% to $10.2 million in 2025.
• Per Business Quant, the three latest TRVI Operating Expenses figures stand at $10.2 million (Q4 2025), $13.9 million (Q3 2025), and $13.7 million (Q2 2025).